Nov 5 (Reuters) - Molecular diagnostics firm

BillionToOne raised $273.1 million in its U.S. initial

public offering on Wednesday, pricing its shares above its

marketed range.

The Menlo Park, California-based company sold about 4.6

million shares priced at $60 apiece in the IPO, compared with

its targeted range of $49 and $55, giving it a potential

valuation of about $2.64 billion.

The offering came as U.S. IPO activity rebounded after an

earlier slowdown sparked by market volatility stemming from

President Donald Trump's shifting trade policies.

Investor demand for new listings had strengthened, though

the recent government shutdown caused temporary delays in the

IPO pipeline.

Still, companies were able to proceed by using a provision

that allowed registrations to take effect automatically,

requiring pricing to be set 20 days before the listing rather

than finalizing it the night before.

BillionToOne is a molecular diagnostics company that

develops non-invasive prenatal and oncology blood tests using

its single-molecule sequencing technology.